In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma

Inclusion Criteria:

1. Sign an informed consent form.
2. Age above 18, gender unlimited.
3. Expectation of life above 3 months.
4. Characteristic of disease: ① Pathological analysis confirms the diagnosis of melanoma. ② PET-CT and serum lactate dehydrogenase (LDH) can be used for auxiliary diagnosis. ③Diameter of at least one solid tumor ≥ 1cm.
5. KPS score: ≥70%.
6. Eastern Cooperative Oncology Group (ECOG) score: 0-2 grade.
7. (Within a week) Complete blood count: hemoglobin≥90g/L, leukocyte ≥ 4.0×109/L, neutrophilic granulocyte ≥ 2.0×109/L, platelet ≥ 100.0×109/L; Renal function: creatinine ≤ 180 umol/L.
8. Never accepted radiation or chemotherapy, or the interval of radiation or chemotherapy administered above 3 month.
9. Never accepted target drugs or biotherapeutics.
10. Urine pregnancy test negative (selectivity).

Exclusion Criteria:

1. Intolerable to BNCT treatment.
2. Sever coagulation disorders.
3. Poor compliance.
4. Sever complications or infection without control.
5. Pregnant woman or woman in lactation period.
6. Patients with metallic instruments (such as pacemaker, artificial limb).
7. Boron concentration in tumor tissue was \<1.5 times that in blood.
8. Age\<18.